Effect of the <scp>glucagon‐like</scp> peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes

Effect of the <scp>glucagon‐like</scp> peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes

To investigate the hypothesis that weight loss with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide alone would lead to a greater reduction in the proportion of fat to lean tissue mass when compared to caloric restriction (CR) alone, as well as when compared to treatment with sita...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Egile Nagusiak:	Heidi J. Silver, Dianna Olson, Dustin Mayfield, Patricia A. Wright, Hui Nian, Mona Mashayekhi, John R. Koethe, Kevin D. Niswender, James M. Luther, Nancy J. Brown
Formatua:	Artigo
Hizkuntza:	ingelesa
Argitaratua:	2023
Sarrera elektronikoa:	https://doi.org/10.1111/dom.15113
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes
nork: Mona Mashayekhi, et al.
Argitaratua: (2023)

Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
nork: Mona Mashayekhi, et al.
Argitaratua: (2022)

Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
nork: Adams, Jessica M., et al.
Argitaratua: (2018)

Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
nork: Jessica M. Adams, et al.
Argitaratua: (2018)

Ethanol Preference in <i><scp>D</scp>rosophila melanogaster</i> is Driven by Its Caloric Value
nork: Jascha B. Pohl, et al.
Argitaratua: (2012)

Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real‐world <scp>UK</scp> data: A clinical evaluation of a multi‐ethnic population
nork: Laurence J. Dobbie, et al.
Argitaratua: (2024)

Neuroprotective and anti‐apoptotic effects of liraglutide on <scp>SH</scp>‐<scp>SY</scp>5Y cells exposed to methylglyoxal stress
nork: Mohit Sharma, et al.
Argitaratua: (2013)

Liraglutide: another reason to target prediabetes?
nork: Murphy, Conor F., et al.
Argitaratua: (2017)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials
nork: Subodh Verma, et al.
Argitaratua: (2020)

Gut microbiome differences between metformin‐ and liraglutide‐treated T2<scp>DM</scp> subjects
nork: Zhang Wang, et al.
Argitaratua: (2017)

Sarcopenia, and its association with cardiometabolic and functional characteristics in <scp>T</scp>aiwan: Results from <scp>I</scp>‐<scp>L</scp>an <scp>L</scp>ongitudinal <scp>A</scp>ging <scp>S</scp>tudy
nork: Li‐Kuo Liu, et al.
Argitaratua: (2014)

The novel <scp>GIP</scp>, <scp>GLP</scp>‐1 and glucagon receptor agonist retatrutide delays gastric emptying
nork: Shweta Urva, et al.
Argitaratua: (2023)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in <scp>J</scp>apanese patients with type 2 diabetes: a 26‐week randomized phase <scp>III</scp> study
nork: Jun‐ichiro Miyagawa, et al.
Argitaratua: (2015)

Liraglutide and cardiovascular outcomes in adults with overweight or obesity: <scp>A</scp><i>post hoc</i> analysis from <scp>SCALE</scp> randomized controlled trials
nork: Melanie J. Davies, et al.
Argitaratua: (2017)

Insulinoma‐released exosomes activate autoreactive marginal zone‐like <scp>B</scp> cells that expand endogenously in prediabetic <scp>NOD</scp> mice
nork: Roman Bashratyan, et al.
Argitaratua: (2013)

Efficacy and safety of liraglutide compared to sulphonylurea during <scp>R</scp>amadan in patients with type 2 diabetes (<scp>LIRA‐R</scp>amadan): a randomized trial
nork: Sami T. Azar, et al.
Argitaratua: (2016)

Trends in purchases and intake of foods and beverages containing caloric and low‐calorie sweeteners over the last decade in the <scp>U</scp>nited <scp>S</scp>tates
nork: Carmen Piernas, et al.
Argitaratua: (2013)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in <scp>J</scp>apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase <scp>III</scp> study
nork: Masato Odawara, et al.
Argitaratua: (2015)

<scp>SIRT</scp>1 but not its increased expression is essential for lifespan extension in caloric‐restricted mice
nork: Evi M. Mercken, et al.
Argitaratua: (2013)

Visceral adipose tissue measured by <scp>DXA</scp> correlates with measurement by <scp>CT</scp> and is associated with cardiometabolic risk factors in children
nork: Tyler A. Bosch, et al.
Argitaratua: (2014)

418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss
nork: Mashayekhi, Mona, et al.
Argitaratua: (2022)

Aspiration risk with glucagon‐like peptide 1 (<scp>GLP</scp>‐1) agonists
nork: Mincho Marroquin-Harris, et al.
Argitaratua: (2023)

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: <scp>H</scp>igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
nork: Carlos Alatorre, et al.
Argitaratua: (2017)

Alterations of <scp>SIRT1</scp>/<scp>SIRT3</scp> subcellular distribution in aging undermine cardiometabolic homeostasis during ischemia and reperfusion
nork: Jingwen Zhang, et al.
Argitaratua: (2023)

Thigh fat and muscle each contribute to excess cardiometabolic risk in <scp>South</scp><scp>Asians</scp>, independent of visceral adipose tissue
nork: Sophie V. Eastwood, et al.
Argitaratua: (2014)

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>)
nork: Chantal Mathieu, et al.
Argitaratua: (2014)

The effects of graded caloric restriction: <scp>XII</scp>. Comparison of mouse to human impact on cellular senescence in the colon
nork: Luigi Fontana, et al.
Argitaratua: (2018)

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
nork: Kim, Sun H., et al.
Argitaratua: (2013)

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
nork: Sun H. Kim, et al.
Argitaratua: (2013)

Dual <scp>glucagon‐like peptide</scp>‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity
nork: Rajna Golubić, et al.
Argitaratua: (2024)

<scp>DPAM</scp>: A domain parser for <scp>AlphaFold</scp> models
nork: Jing Zhang, et al.
Argitaratua: (2022)

<scp>GluN2C</scp>/<scp>GluN2D</scp> subunit‐selective <scp>NMDA</scp> receptor potentiator <scp>CIQ</scp> reverses <scp>MK</scp>‐801‐induced impairment in prepulse inhibition and working memory in <scp>Y</scp>‐maze test in mice
nork: Pratyush Suryavanshi, et al.
Argitaratua: (2013)

Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the <scp>DUAL IV</scp> trial
nork: Helena W. Rodbard, et al.
Argitaratua: (2016)

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the <scp>FIGHT</scp> trial
nork: João Sérgio Neves, et al.
Argitaratua: (2022)

Simultaneous Determination of Eleven Major Flavonoids in the Pollen of <i>Typha angustifolia</i> by <scp>HPLC</scp>‐<scp>PDA</scp>‐<scp>MS</scp>
nork: Weiwei Tao, et al.
Argitaratua: (2011)

Glucagon-like peptide 1 and appetite
nork: Dailey, Megan J., et al.
Argitaratua: (2013)

Glucagon-like peptide 1 and appetite
nork: Megan J. Dailey, et al.
Argitaratua: (2013)

Association of <scp>glucagon‐like peptide</scp>‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
nork: Toshiko Kobori, et al.
Argitaratua: (2023)

Investigating <scp>G</scp> protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast
nork: Chris J. Weston, et al.
Argitaratua: (2014)

Comparing sensitivity and specificity of screening mammography in the <scp>U</scp>nited <scp>S</scp>tates and <scp>D</scp>enmark
nork: Katja Kemp Jacobsen, et al.
Argitaratua: (2015)